secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001193125-25-067871
Event type: other_material
Sentiment:  positive
Materiality: 0.95
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corcept's Phase 3 ROSELLA trial of relacorilant meets primary endpoint; PFS and OS improved significantly
--------------------------------------------------------------------------------

- 30% risk reduction in PFS (HR 0.70, p=0.008); median PFS 6.5 vs 5.5 months for nab-paclitaxel alone.
- Interim OS also positive: median OS 16.0 vs 11.5 months (HR 0.69, p=0.012).
- Relacorilant well-tolerated; no new safety signals; safety comparable between groups.
- Company expects to submit NDA in Q3 2025 and MAA shortly thereafter.
- Trial enrolled 381 patients globally; biomarker selection not required.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000119312525067871/0001193125-25-067871-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000119312525067871/d924664d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-067871

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer